Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2321-2328

  Eom, Ki Seong ^a   Kim, Hee Je ^a   Cho, Byung Sik ^a   Choi, Su Mi ^a   Lee, Dong Gun ^a   Lee, Seung Eun ^a   Yahng, Seung Ah ^a   Kim, Yoo Jin ^a   Lee, Seok ^a   Min, Chang Ki ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Park, Chong Won ^a   Min, Woo Sung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute myeloid leukemia; Elderly; Gemtuzumab ozogamicin; Stem cell transplant

Indexed keywords

BUSULFAN; CD33 ANTIGEN; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; ENOCITABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MITOXANTRONE; TACROLIMUS;

ABSCESS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ANTIMICROBIAL THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CELLULITIS; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FEVER; FOLLOW UP; GERIATRIC PATIENT; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SINGLE DRUG DOSE; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; WHOLE BODY RADIATION;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 82255163500     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.587562     Document Type: Article

References (26)

1. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869-3876. (Pubitemid 35396851)
2. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73. (Pubitemid 43996625)
3. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
4. Gorin NC, Labopin M, Pichard P, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000;110:887-893.
5. Lashkari A, Lowe T, Collisson E, et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients 4 or = 60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant 2006;12:466-471. (Pubitemid 43380963)
6. Oriol A, Ribera JM, Esteve J, et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica 2004;89:791-800. (Pubitemid 38986951)
7. Tomas X, Suciu S, Rio B, et al. Autologous stem cell transplantation after complete remission and f rst consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007;92:389-396. (Pubitemid 350143549)
8. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304-2312. (Pubitemid 41748028)
9. Gupta V, Daly A, Lipton JH, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 2005;11:764-772. (Pubitemid 41403758)
10. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008;14:282-289. (Pubitemid 351218198)
11. Herr AL, Labopin M, Blaise D, et al. HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia 2007;21:129-135. (Pubitemid 44929343)
12. Eom KS, Kim HJ, Min WS, et al. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. Eur J Haematol 2007;79:398-404.
13. Shafer LG, Tommerup N, editors. ISCN 2005: an international system for human cytogenetic nomenclature (2005). Basel, Switzerland: S Karger; 2005.
14. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
15. Kim HJ, Min WS, Eom KS, et al. Autologous stem cell transplantation using modif ed TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in f rst complete remission. Bone Marrow Transplant 2004;34:215-220.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15: 825-828.
17. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:1395-1400. (Pubitemid 46239569)
18. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure signif cantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-1582. (Pubitemid 37022544)
19. Chevallier P, Prebet T, Turlure P, et al. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:165-170.
20. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004;103:78-84. (Pubitemid 38029921)
21. Sperr WR, Florian S, Hauswirth AW, Valent P. CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma 2005;46:1115-1120. (Pubitemid 41087015)
22. van der Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the ef cacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004;18:983-988. (Pubitemid 38714624)
23. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in f rst relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16: 1627-1636.
24. Sievers EL, Larson RA, Stadtmauer EA, et al. Ef cacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in f rst relapse. J Clin Oncol 2001;19:3244-3254. (Pubitemid 32591442)
25. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug ef ux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168-4170. (Pubitemid 46743379)
26. Burnett AK, Hills RK, Milligan D, et al. Identif cation of patients with acute myeloblastic leukemia who benef t from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369-377.